Demystifying Amgen: Insights from 13 Analyst Comments – Amgen (NASDAQ: AMGN )
Over the past three months, 13 analysts have shared reviews of Amgen AMGNrevealing different views ranging from bullish to bearish.
The table below provides a concise view of its recent ratings, showing how sentiment has changed over the past 30 days and comparing it to previous months.
| bullish | somewhat bullish | indifferent | A bit bearish | Bearish | |
|---|---|---|---|---|---|
| Overall rating | 2 | 5 | 4 | 2 | 0 |
| last 30 days | 0 | 0 | 0 | 1 | 0 |
| 1 million years ago | 1 | 1 | 1 | 0 | 0 |
| 2M ago | 1 | 2 | 2 | 0 | 0 |
| 3M ago | 0 | 2 | 1 | 1 | 0 |
Analysts recently reviewed Amgen and provided 12-month price targets. The average target is $340.38, with the highest estimate at $405.00 and the lowest estimate at $215.00. This upward trend is evident, with the current average price representing a 0.18% increase from the previous average price target of $339.78.
Explore Analyst Ratings: An In-Depth Overview
An in-depth look at recent analyst behavior reveals Amgen’s standing among financial experts. The summary below provides an overview of the leading analysts, their most recent assessments, and changes to ratings and price targets.
| analyst | Analyst Company | action taken | grade | Current price target | Previous price target |
|---|---|---|---|---|---|
| Tim Anderson | B of A security | declare | poor performance | $256.00 | – |
| Gregory Renza | Royal Bank of Canada Capital | reduce | Outperform | $330.00 | $360.00 |
| Jeff Meacham | Citigroup | declare | neutral | $335.00 | – |
| Michael Yee | Jeffries | maintain | purchase | $380.00 | $380.00 |
| Colin Bristow | UBS | reduce | neutral | $326.00 | $335.00 |
| Olivia Breyer | Cantor Fitzgerald | maintain | overweight | $405.00 | $405.00 |
| Aaron Weber | TD Cowan | improve | purchase | $383.00 | $381.00 |
| Aaron Gall | Bernstein | declare | Outperform | $380.00 | – |
| Robin Kanaskas | trust securities | improve | catch | $333.00 | $320.00 |
| Carter Gould | barclays bank | improve | Equal weight | $315.00 | $300.00 |
| Olivia Breyer | Cantor Fitzgerald | declare | overweight | $405.00 | – |
| Gregory Renza | Royal Bank of Canada Capital | maintain | Outperform | $362.00 | $362.00 |
| Brian Scone | Baird | maintain | poor performance | $215.00 | $215.00 |
Key insights:
- Action taken: Analysts adjust their recommendations based on changing market conditions and company performance. Whether they “maintain,” “raise,” or “lower” their stance reflects their reaction to the latest Amgen-related developments. This information provides a snapshot of how analysts view a company’s current situation.
- grade: Analysts provide forecast insights, with qualitative ratings ranging from “Outperform” to “Underperform.” These ratings convey expectations for Amgen’s relative performance relative to the broader market.
- Price target: Analysts set price targets as estimates of a stock’s future value. Comparing current and previous price targets can provide insight into how analyst expectations have changed over time. This information can be valuable to investors looking for a consensus view of a stock’s potential future performance.
Looking at these analyst reviews, along with other financial metrics, can help get a complete picture of Amgen’s market position. Stay informed and make data-driven decisions with our ratings tables.
Stay up to date with Amgen analyst ratings.
Learn more about Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and inflammatory disease treatments Enbrel and Otezla. Amgen launched its first cancer treatment, Vectibix, in 2006, and sells bone-strengthening drugs Prolia/Xgeva (approved in 2010) and Evenity (2019). The acquisition of Onyx strengthens the company’s Kyprolis oncology treatment portfolio. Recent launches include Repatha (lowering cholesterol), Aimovig (migraines), Lumakras (lung cancer) and Tezspire (asthma). The 2023 Horizon acquisition brought in multiple rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing portfolio of biosimilars.
Financial Insights: Amgen
Market capitalization: The company’s market capitalization is higher than the industry average, highlighting its scale advantage and demonstrating strong market influence.
Positive revenue trends: An examination of Amgen’s financials over three months reveals some positives. The company achieved impressive revenue growth rates 23.18% As of September 30, 2024, revenue has grown significantly. Compared to its industry peers, the company’s growth rate is higher than the average among its peers in the Healthcare industry.
net income: The company’s net profit margin performance is excellent and exceeds the industry average. Impressive net profit margin 33.28%, The company has strong profitability and effective cost control.
Return on Equity (ROE): Amgen’s ROE exceeds industry standards, highlighting the company’s superior financial performance. has an impressive 42.08% ROE, the company’s effective use of shareholders’ equity capital.
Return on assets (ROA): The company’s ROA performance is excellent and exceeds the industry average. Have an impressive ROA 3.11%, The company demonstrates efficient use of assets.
Debt Management: Amgen’s debt-to-equity ratio is significantly higher than the industry average, reaching 8.02. This shows a greater reliance on borrowed funds and raises concerns about financial leverage.
Analyst Rating: Simplified
Analysts are experts in banking and financial systems who specialize in reporting on specific stocks or specific industries. Their comprehensive research includes attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to produce what are known as analyst ratings for stocks. Typically, analysts evaluate and rate each stock on a quarterly basis.
Analysts can enhance their assessments by incorporating forecasts on metrics such as growth, earnings and revenue to provide additional guidance to investors. It’s important to acknowledge that while analysts are experts on stocks and industries, they are also human and express their own opinions when providing insights.
BREAKING: Wall Street’s next big mover
Benzinga’s top analysts just discovered a stock that’s poised for explosive growth. This under-the-radar company could surge more than 200% as a major market shift unfolds. Click here for emergency details.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market news and data brought to you by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. all rights reserved.
